MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

Search

Blueprint Medicines Corp

Slēgts

SektorsVeselības aprūpe

87.01 1.17

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

86.93

Max

87.68

Galvenie mērījumi

By Trading Economics

Ienākumi

6.3M

-50M

Pārdošana

18M

146M

EPS

-0.79

Peļņas marža

-34.131

Darbinieki

649

EBITDA

6.3M

-27M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+48.59% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 1. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

5.4B

Iepriekšējā atvēršanas cena

85.84

Iepriekšējā slēgšanas cena

87.01

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bullish Evidence

Blueprint Medicines Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 25. apr. 17:01 UTC

Peļņas
Galvenie tirgus virzītāji

Aon Shares Sink After 1Q Profit Falls, Sales Miss Estimates

2025. g. 25. apr. 16:10 UTC

Peļņas
Galvenie tirgus virzītāji

Coursera Shares Rise After 1Q Beat, Better-Than-Expected Revenue View

2025. g. 26. apr. 18:14 UTC

Peļņas

Tech Executives Are Starting to Talk Tariffs. What It May Mean for Apple, Amazon Earnings -- Barrons.com

2025. g. 26. apr. 15:00 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Trump 2.0 Era Brings Flurry of Crypto Deals -- WSJ

2025. g. 26. apr. 08:20 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 25. apr. 21:24 UTC

Top Ziņas

Cargo Shipments From China to the U.S. Dwindle -- WSJ

2025. g. 25. apr. 20:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 25. apr. 20:45 UTC

Top Ziņas

Stocks Claw Back Most of April's Tariff Losses -- WSJ

2025. g. 25. apr. 20:39 UTC

Peļņas

The Score: Tesla, Capital One, Boeing and More Stocks That Defined the Week -- WSJ

2025. g. 25. apr. 20:37 UTC

Top Ziņas

Trump Administration Lays Out Tariff Roadmap to Streamline Trade Talks -- WSJ

2025. g. 25. apr. 20:19 UTC

Top Ziņas

Nasdaq Climbs More Than 1% as Stocks Finish Strong Week -- WSJ

2025. g. 25. apr. 20:15 UTC

Peļņas

Week's Best: A Dividend Expert's Best Advice -- Barrons.com

2025. g. 25. apr. 19:23 UTC

Tirgus saruna

U.S. Natural Gas Futures Extend Weekly Losses -- Market Talk

2025. g. 25. apr. 19:18 UTC

Tirgus saruna

Oil Futures End Choppy Week With Losses -- Market Talk

2025. g. 25. apr. 18:47 UTC

Tirgus saruna

Gold Extends Pullback to Close Week -- Market Talk

2025. g. 25. apr. 18:39 UTC

Top Ziņas

Nasdaq, Dow Industrials About Flat; Analysts Caution on Trump Tariffs -- WSJ

2025. g. 25. apr. 18:34 UTC

Iegādes, apvienošanās, pārņemšana

Goldman Sachs Upgrades Schwab Stock. Here's Why. -- Barrons.com

2025. g. 25. apr. 18:32 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2025. g. 25. apr. 18:32 UTC

Tirgus saruna
Peļņas

Carriers See Tariffs Driving Up Phone Prices, Slowing Upgrades -- Market Talk

2025. g. 25. apr. 18:08 UTC

Peļņas

Sphere Entertainment Deal Is a Win for Shareholders as Banks Take a Hit -- Barrons.com

2025. g. 25. apr. 17:55 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By 2 to 483 -- Market Talk

2025. g. 25. apr. 17:40 UTC

Top Ziņas

Consumers Continue to Sour on the Economy -- 4th Update

2025. g. 25. apr. 17:38 UTC

Peļņas

Centene Stock Falls on Medicaid Cost Worries -- Barrons.com

2025. g. 25. apr. 17:07 UTC

Tirgus saruna

Oil Futures Turn Higher in Quiet Trade -- Market Talk

2025. g. 25. apr. 16:54 UTC

Tirgus saruna
Peļņas

Mobile Carriers See Stronger Activity on Bigger Price Tags, Tariffs -- Market Talk

2025. g. 25. apr. 16:46 UTC

Peļņas

Reddit, Meta, and Pinterest Stocks Rise. How Alphabet's Earnings Are Giving Them a Boost. -- Barrons.com

2025. g. 25. apr. 16:20 UTC

Tirgus saruna
Peļņas

Basic Materials Roundup: Market Talk

2025. g. 25. apr. 16:12 UTC

Top Ziņas

Dow Industrials Fall; China Plans Economic Support During Trade Battle -- WSJ

2025. g. 25. apr. 16:03 UTC

Peļņas

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

2025. g. 25. apr. 15:52 UTC

Tirgus saruna

Grains Mixed on Low Volume Trade -- Market Talk

Salīdzinājums

Cenas izmaiņa

Blueprint Medicines Corp Prognoze

Cenas mērķis

By TipRanks

48.59% augšup

Prognoze 12 mēnešiem

Vidējais 130.25 USD  48.59%

Augstākais 155 USD

Zemākais 100 USD

Pamatojoties uz 18 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Blueprint Medicines Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

18 ratings

14

Pirkt

4

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

83.5 / N/AAtbalsts un pretestība

Īstermiņā

Very Strong Bullish Evidence

Vidējā termiņā

Strong Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Blueprint Medicines Corp

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.